Craneware shares are likely to come under pressure after the healthcare financial software group said full-year results would fall short of market expectations, blaming a late slowdown in 340B revenue conversion and the deferral of several large enterprise contracts.
The AIM-listed company now expects FY26 revenue of US$205-208 million and adjusted EBITDA of US$65-67 million, both broadly flat on the prior year.
The shortfall stems largely from Craneware’s 340B business, where the final weeks of the year proved materially weaker than anticipated.
While the group has identified around $500 million of outstanding qualifying drug purchases for hospital customers, the pace at which these opportunities converted into actual sales slowed sharply as pharmaceutical manufacturers expanded restrictions on the supply of certain 340B-priced medicines.
A small number of significant enterprise contracts have also slipped into FY27.
This is not what investors wanted to hear, and shares were down 20% at the time of writing.